FDA Issues Black Box Warning on Drug Linked to Mass KillingsLily Dane Mefloquine has been used by U.S. troops for years, and is also available to civilians traveling to hot spots. It was developed by the US Army and became available on the commercial market in 1989. It is one of the most commonly prescribed anti-malarial drugs in the U.S., with about 119,000 prescriptions written in the first half of 2013. The FDA warning about the mefloquine was issued on July 29, 2013 in a public safety announcement, which states: The possibility that Sgt. Bales was given mefloquine while in Afghanistan and Iraq was raised earlier this month when the FDA released an adverse event notification filed by an anonymous pharmacist in 2012. The notification states that an unnamed soldier who took the drug murdered 17 Afghan citizens the same number included in Bales initial charging documents. The adverse event notification report was obtained by Military Times on July 5 via the Freedom of Information Act. It states: An FDA adverse event report means that a patient developed symptoms while using a drug, but does not necessarily mean the medication caused any specific health problems. However, the medically confirmed report does suggest that either the source of the notification was someone who was directly involved with the patients medical care or that the drug manufacturer received documentation verifying the information, according to Dr. Remington Nevin, a leading mefloquine researcher who has also filed a FOIA request for the information. Lily Dane is a staff writer for The Daily Sheeple, where this article first appeared. Her goal is to help people to Wake the Flock Up! 